TuHURA Biosciences Share Holder Equity 2010-2024 | HURA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

TuHURA Biosciences share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

TuHURA Biosciences share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.8B
Vertex Pharmaceuticals (VRTX)	$122.6B
Gilead Sciences (GILD)	$109.8B
Bristol Myers Squibb (BMY)	$107B
Regeneron Pharmaceuticals (REGN)	$106.1B
CSL (CSLLY)	$96.1B
GSK (GSK)	$78.8B
Alnylam Pharmaceuticals (ALNY)	$38.1B
Argenex SE (ARGX)	$34B
Biogen (BIIB)	$27.1B
BioNTech SE (BNTX)	$26.4B
Illumina (ILMN)	$22.9B
BeiGene (BGNE)	$21.5B
Moderna (MRNA)	$20.5B
Genmab (GMAB)	$15.1B
BioMarin Pharmaceutical (BMRN)	$13.4B
Exact Sciences (EXAS)	$13B
Insmed (INSM)	$12.7B
Incyte (INCY)	$12.6B
Vaxcyte (PCVX)	$12.6B
Sarepta Therapeutics (SRPT)	$12.2B
Bio-Techne Corp (TECH)	$11.1B
QIAGEN (QGEN)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.7B
Exelixis (EXEL)	$8.2B
Legend Biotech (LEGN)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B
Repligen (RGEN)	$8.1B
Revolution Medicines (RVMD)	$7.9B